| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-10-30 | Poxel (France) Sumitomo Dainippon Pharma (Japan) | imeglimin | type 2 diabetes | development - commercialisation | Metabolic diseases | Development agreement |
| 2017-10-26 | Wave LIfe Sciences (USA - MA) | manufacturing facility and office space in Lexington | opening of new premises | Rare diseases - Genetic diseases | Opening of new premises | |
| 2017-10-25 | Gensight Biologics (France) | chief medical officer | nomination | Rare diseases - Genetic diseases - Ophtalmological diseases | Nomination | |
| 2017-10-25 | Poietis (France) BASF (Germany) | 3D bioprinting technology for advanced skin care applications | collaboration | Technology - Services | Collaboration agreement | |
| 2017-10-24 | BioInvent (Sweden) | chief executive officer | resignation | Cancer - Oncology | Resignation | |
| 2017-10-23 | Basilea Pharmaceutica (Switzerland) Astellas Pharma (Japan) | Cresemba® (isavuconazole) | aspergillosis, invasive mucormycosis | development - licensing - commercialisation - promotion | Infectious diseases | Milestone |
| 2017-10-23 | VBL Therapeutics (Israel) | gene therapy manufacturing plant in Modiin | opening of new premises | Cancer - Oncology - Technology - Services | Opening of new premises | |
| 2017-10-23 | Adaptimmune (UK) | vice-president | nomination | Cancer - Oncology - Autoimmune diseases | Nomination | |
| 2017-10-23 | Cytosen Therapeutics (USA - TX) | member of the scientific and medical advisory board | nomination | Cancer - Oncology | Nomination | |
| 2017-10-19 | Merck KGaA (Germany) | Carlsbad facility | opening of new premises | Technology - Services | Opening of new premises | |
| 2017-10-19 | Pharmaxis (Australia) | nomination | Fibrotic diseases - Inflammatory diseases | Nomination | ||
| 2017-10-19 | apceth (Germany) DCPrime (The Netherlands) | cancer vaccines based on DCPrime’s technology platform DCOne® | manufacturing - production | Cancer - Oncology | Production agreement | |
| 2017-10-18 | Arbutus Biopharma (Canada) Gritstone Oncology (USA - CA) | lipid nanoparticle (LNP) technology | licensing | Cancer - Oncology | Licensing agreement | |
| 2017-10-18 | Protalix BioTherapeutics (Israel) Chiesi Farmaceutici (Italy) | pegunigalsidase alfa (PRX-102 - alpha-galactosidase-A) | Fabry disease | development - commercialisation | Rare diseases - Genetic diseases | Development agreement |
| 2017-10-16 | Aimmune Therapeutics (USA - CA) Regeneron Pharmaceuticals (USA - NY) Sanofi (France) | AR101 and dupilumab | peanut allergy | clinical research | Allergic diseases | Clinical research agreement |
| 2017-10-12 | Bavarian Nordic (Denmark) SGS (Switzerland) | universal vaccine candidate designed to induce protective immune responses against both subtypes (A & B) of RSV | Respiratory Syncytial Virus (RSV) infection | collaboration | Infectious diseases | Collaboration agreement |
| 2017-10-11 | Merck KGaA (Germany) | Life Science Center in Burlington | opening of new premises | Technology - Services | Opening of new premises | |
| 2017-10-10 | Blueprint Medicines (USA - MA) | vice-president | nomination | Cancer - Oncology - Rare diseases | Nomination | |
| 2017-10-06 | Amicus Therapeutics (USA - NJ) | VP business and corporate development | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-10-05 | Medivir (Sweden) AMR Centre (UK) | metallo-?-lactamase inhibitor (MBLI) program | beta lactamase resistant infections | licensing | Infectious diseases | Licensing agreement |
